(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Physician-scientist led biotech Regeneron will be responsible for funding preclinical and clinical development and commercialisation activities, while oncology-focused biopharma CytomX will ...

Introduction Therapeutic antibodies are laboratory-engineered proteins designed to replicate the immune system's natural ability to combat dise ...

Regeneron also said it was discontinuing a phase 3 study of REGN1908-1909, a multi-antibody therapy to Fel d 1 being studied as a treatment for cat allergy, due to futility. Image Phil Taylor ...

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

PC hardware is nice, but it’s not much use without innovative software. I’ve been reviewing software for PCMag since 2008, and I still get a kick out of seeing what's new in video and photo ...

Personalized medicine is a therapeutic approach involving the use of an individual’s genetic and epigenetic information to tailor drug therapy or preventive care. Variability exists in ...